Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Pacira BioSciences, Inc. (PCRX) had Revenue of $192.40M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$192.40M
Net Income	$4.65M
Cost of Goods Sold	$44.16M
Gross Profit	$148.24M
Operating Expenses	$188.13M
Operating Income	$4.27M
Non-Operating Income/Expense	$-1.71M
Pre-Tax Income	$2.56M
Normalized Pre-Tax Income	$2.56M
Income after Taxes	$4.65M
Income from Continuous Operations	$4.65M
Consolidated Net Income/Loss	$4.65M
Normalized Income after Taxes	$4.65M
EBIT	$4.27M
EBITDA	$27.37M
Weighted-Average Shares Outstanding (Basic)	39.46M
Weighted-Average Shares Outstanding (Diluted)	40.30M
Earnings per Share (EPS) (Basic)	$0.12
Earnings per Share (EPS) (Diluted)	$0.12
Balance Sheet Financials
Current Assets	$615.22M
Property, Plant, and Equipment	$130.28M
Long-Term Assets	$628.76M
Total Assets	$1.24B
Current Liabilities	$122.01M
Long-Term Debt	$363.12M
Long-Term Liabilities	$449.99M
Total Liabilities	$572.00M
Common Equity	$671.98M
Tangible Shareholders Equity	$366.85M
Shareholders Equity	$671.98M
Common Shares Outstanding	39.82M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$83.14M
Cash Flow from Investing Activities	$31.20M
Cash Flow from Financial Activities	$-67.05M
Beginning Cash	$158.54M
End Cash	$205.88M
Increase/Decrease in Cash	$47.33M
Stock-Based Compensation	$28.50M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.04
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.35
Debt to Equity Ratio	0.54
Gross Margin	77.05%
Operating Margin	2.22%
EBIT Margin	2.22%
EBITDA Margin	--
Pre-Tax Profit Margin	1.33%
Profit Margin	2.42%
Free Cash Flow	$79.08M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.15
Inventory Turnover	0.33
Receiveable Turnover	1.45
Days Sales in Receivables	61.94
Return on Equity	0.69%
Return on Tangible Equity	1.27%
Return on Assets	0.37%
Return on Investments	0.45%
Book Value Per Share	$16.87
Free Cash Flow per Share	$1.96
Operating Cash Flow per Share	$2.06

Data from Zacks Investment Research, Inc.